A field trial of co-administration of azithromycin and ivermectin mass drug administration for scabies and trachoma.

Phase 4

Completed

• Conditions: Infection - Other infectious diseases; Eye - Diseases / disorders of the eye; Scabies; Trachoma; Skin - Other skin conditions

• Registration Number: ACTRN12615001199505
• Lead Sponsor: Murdoch Childrens Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-11-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 25000

Inclusion Criteria

All community members resident in Choiseul province, Solomon Islands able to be included in the study. Treatment is offered to all individuals regardless of the presence/absence of scabies/impetigo/trachoma at the time of MDA.

Exclusion Criteria

- Allergy to any of the components of the allocated drug regimen
- Currently on, or has taken ivermectin in the previous 7 days
- Clinical diagnosis of crusted scabies: participants with severe or crusted scabies will be treated with 2 doses of ivermectin (except if ivermectin is contraindicated as outlined above) in conjunction with twice weekly permethrin cream for 1 month, with review at 1,2,3,12 and 24 months. Efforts will be made to control these cases intensively to prevent the high force of infection associated with these crusted cases from diminishing the effect of the MDA.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Coverage of the MDA in the study population, separate for trachoma and scabies MDA.<br>This is calculated by<br>Primary Method: Comparing study records to community population data<br>Secondary Method: Capture-recapture comparing population present when the D1 and D8 doses of Ivermectin are administered [1 Month post first dose administration.]